Global Pharmatech, Inc. Completes the Transaction to Acquire Botaniex, Inc.
Hong Kong, China, March 8, 2023 (OTC News Disclosures) -- Global Pharmatech, Inc. (OTC Pink: GBLP) ("GBLP" or the "Company"), is pleased to announce that it has completed the transaction to acquire 100% of the issued and outstanding shares of Botaniex, Inc. (the “Botaniex”) with Botaniex, Inc., a Delaware corporation, which is operating in Changsha, China, through execution of a definitive Share Exchange Agreement on December 18, 2022, whereby GBLP has acquired all of the issued and outstanding shares of Botaniex (the “Transaction”).
Pursuant to the Transaction, an aggregate of 112,360,000 fresh, restricted shares of GBLP Common Stock was issued in exchange for the shares of Botaniex Common Stock issued and outstanding. As of Closing, Botaniex Shareholders shall own, in the aggregate, not less than twenty-eight percent (28%) of the total issued and outstanding shares of GBLP Common Stock outstanding, on a fully diluted basis,
After the Closing, Mr. Yong Sheng, the President of GBLP, resigned as Chief Executive Officer, President, Treasury and Secretary of GBLP immediately, but thereafter will remain a Director of GBLP’s Board of Directors. At the same time, Melson Liao, the President of Botaniex, was elected to serve as Director, Chief Executive Officer, President, Treasury and Secretary of GBLP.
Additional information about the Transaction, and the vision of the companies such as the development strategies, business models, competitive strategies and etc., will be provided in the coming Annual Disclosures and the future press reports
About GBLP
Global Pharmatech, Inc, through its subsidiaries, discovers, develops, manufactures and markets proprietary therapeutical products based on Traditional Chinese Medicine (TCM) while utilizing modern facilities and advanced R&D technologies. The company’s growth strategy is to establish new ventures and/or joint venture in USA, China, and Canada.
About Botaniex, Inc.
Botaniex, Inc. is a Delaware Corporation incorporated in 2005, and it has been operating through its 100% owned subsidiary of Changsha Botaniex, Inc. in China since 2005.
Changsha Botaniex, Inc. is a market-oriented supplier & manufacturer of natural ingredients (botanical extracts/herbal extracts and herbal formulations) for the Industries of Dietary Supplements, Functional Foods, Functional Beverages, Cosmetics and Pharmaceuticals. By co-operating with the strategic partners, Botaniex’s R&D team is dedicated to development of the new natural ingredients and the herbal formulations focusing on men’s health and women’s health. In addition, both the advanced equipment and sophisticated technology are employed to produce the high quality and customized botanical extracts and herbal formula. We also provide customers with value added services such as Private Labels, Contract Manufacturing, and etc.
Currently Changsha Botaniex, Inc. owns the patents as follows:
- A Technology to Extract Sea Buckthorn Oil by Enzyme and CO2 (Super-Critical Fluid Extraction (Patent Number: ZL 2014-1-0009702.6);
- A Technology to Extract L-Theanine from Green Tea (Patent Number: ZL 2015-1-0578407.7);
- A Technology to Extract Actinidin from Kiwi Fruit (Patent Number: ZL 2013-1-0731769.6);
In addition, Botaniex owns the following Trademarks:
- EJACON – a brand used for men’s health products (Trademark#: 4998788)
- Slimmer-Trimmer – a brand used for weight management; (Trademark#: 4998779)
- Twin-Peaks – a brand used for women’s beauty (Trademark#: 5469534)
For further information about Botaniex and its products, visit the company’s website at www.botaniex.com
Forward-Looking Information:
This news release contains certain forward-looking statements, which include any statements made in this release which are not historical facts, such as statements concerning potential future developments affecting the business, prospects, financial condition and other aspects of the companies to which this release pertains. The actual results of the specific items described in this release, and the company’s operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of each company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company’s dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement.
Investor Relations
Melson Liao
CEO & President
Email: ir@botaniex.com
Phone#: +86 731 88718666